Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 13132Neoplasms 10477Carcinoma, Non-Small-Cell Lung 6870Prostatic Neoplasms 6268Colorectal Neoplasms 5945Lung Neoplasms 5102Multiple Myeloma 3576Pancreatic Neoplasms 3561Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3507Carcinoma, Hepatocellular 3271Ovarian Neoplasms 3168Melanoma 3139Stomach Neoplasms 3056Lymphoma 2982Head and Neck Neoplasms 2603Recurrence 2556Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2327Brain Neoplasms 2310Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2191Uterine Cervical Neoplasms 2191Glioblastoma 2014Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1847Esophageal Neoplasms 1800

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1berzosertib 1aldesleukin 1Platinum 1Immunoglobulin G 1Gemcitabine 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Bladder Urothelial Carcinoma × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

NCT03935347 2020-01-02

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Roswell Park Cancer Institute

Phase 2 Withdrawn
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡